1. Toward elucidating the full spectrum of mite allergens — state of the art
- Author
-
Airo Tategaki, Takashi Katsutani, Mitsuo Yamashita, Kazuhisa Ono, Osamu Suzuki, Tsunehiro Aki, Seiji Kawamoto, Takashi Fujimura, Seiko Shigeta, Yoshikatsu Murooka, and Shinji Tsuboi
- Subjects
Allergy ,biology ,medicine.medical_treatment ,Pyroglyphidae ,Bioengineering ,Immunotherapy ,respiratory system ,biology.organism_classification ,medicine.disease ,medicine.disease_cause ,Applied Microbiology and Biotechnology ,respiratory tract diseases ,Allergen ,Antigen ,immune system diseases ,Immunology ,otorhinolaryngologic diseases ,biology.protein ,medicine ,Mite ,Villin ,Gelsolin ,Biotechnology - Abstract
Our research has focused on the molecular design of immunotherapeutic vaccines and the advancement of mite-allergy diagnosis. Here, we describe the research history of the major group 1 and group 2 allergens, immunoelectrophoretic analyses covering the complete spectrum of mite allergens, our results on allergens with distinctive characteristics (a conjunctival congestion-eliciting antigen [LM2], an immunotherapeutic antigen [HM2] with high efficacy and without definite adverse reactions, and a potent T-cell stimulatory antigen [HM1] with secretion of IFN-γ), the full spectrum and immunochemical properties of the major and other important mite allergens (including our newly described allergens: a pan-allergen [tropomyosin, group 10], a potent T-cell stimulatory allergen [M-177, apolipophorin, group 14] and its peptide fragments Mag1 and Mag3, a moderate IgE-binding allergen [gelsolin/villin, group 16], an EF-hand Ca2+-binding allergen [group 17], and a less IgE-binding allergen [heat shock protein 70]), and prospects for the development of immunotherapeutic and diagnostic agents.
- Published
- 2002
- Full Text
- View/download PDF